Huddy J R, Huddy F M S, Markar S R, Tucker O
Department of Surgery & Cancer, Imperial College London, London, UK.
Department of Oesophago-Gastric Surgery, Royal Surrey County Hospital, Guildford, UK.
Dis Esophagus. 2018 Jan 1;31(1):1-11. doi: 10.1093/dote/dox110.
This narrative review aims to evaluate the evidence for the different nutritional approaches employed during neoadjuvant therapy in patients with locoregional esophageal cancer. Patients with esophageal cancer are often malnourished and difficult to optimize nutritionally. While evidence suggests that neoadjuvant therapy can offer a survival advantage, associated toxicity can exacerbate poor nutritional status. There is currently no accepted standard of care regarding optimal nutritional approach. A systematic literature search was undertaken. Studies describing the utilization of an additional nutritional intervention in patients with esophageal cancer receiving neoadjuvant therapy prior to esophagectomy were included. Primary outcome measure was 30-day postoperative mortality after esophagectomy. Secondary outcome measures were loss of weight during neoadjuvant therapy, completion rate of intended neoadjuvant therapy, complications from nutritional intervention, 30-day postoperative morbidity after esophagectomy and quality of life during neoadjuvant treatment. Given the heterogeneity of retrieved articles results was presented as a narrative review. Twenty-five studies were included of which 16 evaluated esophageal stenting, four feeding jejunostomy, three gastrostomy, one nasogastric feeding, and one comparative study of esophageal stenting to feeding jejunostomy. 30-day postoperative mortality was only reported in two of the 26 included studies limiting comparison between nutritional strategies. All studies of esophageal stents reported improvements in dysphagia with reported weight change ranging from -5.4 to +6 kg and one study reported 30-day postoperative mortality after esophagectomy (10%). In patients undergoing esophageal stenting for their neoadjuvant treatment overall migration rate was 29.9%. Studies of laparoscopically inserted jejunostomy were all retrospective reviews that demonstrated an increase in weight ranging from 0.4 to 11.8 kg and similarly no study reported 30-day postoperative mortality. Only one comparative study was included that compared esophageal stents to jejunostomy. This study reported no significant difference between the two groups in respect to complication rates (stents 22% vs. jejunostomy 4%, P = 0.11) or increase in weight (stents 4.4 kg vs. jejunostomy 4.2 kg, P = 0.59). Quality of life was also poorly reported. This review demonstrates the uncertainty on the optimal nutritional approach for patients with resectable esophageal cancer undergoing neoadjuvant treatment prior to esophagectomy. A prospective, multicenter, observational cohort study is needed to determine current practice and inform a prospective clinical trial.
本叙述性综述旨在评估局部区域性食管癌患者新辅助治疗期间采用不同营养方法的证据。食管癌患者常存在营养不良且营养状况难以优化。虽然有证据表明新辅助治疗可带来生存优势,但相关毒性会加剧营养不良状况。目前对于最佳营养方法尚无公认的标准治疗方案。我们进行了系统的文献检索。纳入了描述在接受食管切除术之前接受新辅助治疗的食管癌患者中采用额外营养干预措施的研究。主要结局指标是食管切除术后30天的死亡率。次要结局指标包括新辅助治疗期间的体重减轻、预定新辅助治疗的完成率、营养干预的并发症、食管切除术后30天的发病率以及新辅助治疗期间的生活质量。鉴于检索到的文章具有异质性,结果以叙述性综述的形式呈现。共纳入25项研究,其中16项评估了食管支架置入术,4项评估了空肠造口喂养,3项评估了胃造口术,1项评估了鼻胃管喂养,1项是食管支架置入术与空肠造口喂养的比较研究。在纳入的26项研究中,仅有2项报告了术后30天的死亡率,这限制了营养策略之间的比较。所有关于食管支架的研究均报告吞咽困难有所改善,体重变化范围为 -5.4至 +6千克,1项研究报告了食管切除术后30天的死亡率(10%)。接受新辅助治疗的食管支架置入术患者总体移位率为29.9%。腹腔镜置入空肠造口术的研究均为回顾性综述,显示体重增加范围为0.4至11.8千克,同样没有研究报告术后30天的死亡率。仅纳入了1项比较食管支架与空肠造口术的对照研究。该研究报告两组在并发症发生率(支架组22% vs. 空肠造口术组4%,P = 0.11)或体重增加(支架组4.4千克 vs. 空肠造口术组4.2千克,P = 0.59)方面无显著差异。生活质量方面的报告也较少。本综述表明,对于可切除食管癌患者在食管切除术前接受新辅助治疗时的最佳营养方法存在不确定性。需要开展一项前瞻性、多中心、观察性队列研究以确定当前的实践情况并为前瞻性临床试验提供依据。